Testosterone replacement therapy can help men with confirmed hypogonadism, but it is not a treatment for symptoms or a borderline result in isolation. Safe TRT begins with diagnosis, cause-finding and fertility planning, then continues with individualised treatment and monitoring.
Testosterone replacement therapy is treatment for male hypogonadism: compatible symptoms or signs, consistently low testosterone and a clinical reason why replacement is appropriate. It is not a general answer to fatigue, a shortcut to improved gym performance or a way to optimise an already normal result.
When the diagnosis is sound, TRT can improve sexual symptoms and other consequences of deficiency. It also suppresses the body's own hormone signals and sperm production, can raise haematocrit and requires continuing review. The quality of TRT therefore depends as much on the assessment and monitoring as on the medicine.
TRT replaces testosterone that the body is not producing adequately. In the UK it is available on prescription in formulations including daily gels, shorter-acting intramuscular injections and long-acting testosterone undecanoate injections. The right option depends on diagnosis, symptoms, fertility plans, medical risk, preference, ability to use the medicine correctly and access to monitoring.
Before starting, a clinician should confirm low testosterone on two correctly timed blood tests, investigate the cause, assess fertility plans and establish baseline safety markers. During treatment, symptoms, testosterone, haematocrit and relevant prostate, cardiovascular and metabolic factors are reviewed. A high-quality service should be prepared to adjust, switch or stop treatment when the benefit-risk balance changes.
TRT provides exogenous testosterone—testosterone from outside the body—to restore levels into a physiological range. It can be absorbed through the skin or delivered as an injection. Different testosterone esters and delivery systems change how quickly it enters the circulation and how often it is administered.
Replacement is different from stimulating the testes to produce more testosterone. Once exogenous testosterone is present, the hypothalamus and pituitary reduce luteinising hormone and follicle-stimulating hormone. Natural testicular testosterone production and spermatogenesis fall as a result.
Treatment should improve clinically relevant symptoms and health consequences at a safe physiological exposure without avoidable adverse effects. A laboratory number alone is not a sufficient outcome.
A typical evidence-based assessment looks for all of the following:
The Society for Endocrinology joint position statement considers two morning, fasting results below 8 nmol/L likely to represent hypogonadism in a symptomatic man. Results of 8–12 nmol/L require careful clinical correlation. Values above 12 nmol/L are not usually consistent with hypogonadism. The EAU uses below 12 nmol/L, repeated on at least two occasions alongside symptoms, as a threshold for late-onset hypogonadism.
This is a clinical framework, not a checkout rule. A provider should not turn every man in the borderline range into a patient, nor dismiss a severe secondary pattern without investigating it.
TRT may be inappropriate when the testosterone result is normal, symptoms have a more likely explanation or the underlying suppression is better addressed directly. Examples include untreated sleep apnoea, marked under-fuelling, acute illness, a medicine effect, obesity-related functional suppression or poorly controlled metabolic disease, although some men will still need specialist hormone treatment after those factors are addressed.
TRT is also not the standard treatment for a man actively trying to conceive. It suppresses sperm production. Selected men with secondary hypogonadism may instead need specialist approaches that stimulate endogenous testosterone and spermatogenesis.
Contraindications and cautions vary slightly between guidelines and product information. The EAU lists the following main contraindications:
Severe lower urinary tract symptoms, baseline haematocrit around 48–50% and a family history of venous thromboembolism require additional caution and assessment. Individual UK product information also lists formulation-specific contraindications, excipient allergies and medical precautions.
Prostate history, breast symptoms, urinary symptoms, cardiovascular disease, previous thrombosis, smoking, hypertension, sleep apnoea, migraine, epilepsy, liver or kidney disease and use of anticoagulants should be discussed with the prescriber. The presence of a condition does not always produce the same decision, but hiding it prevents safe prescribing.
The exact formulary and stock position can change. The comparison below describes major UK-licensed routes, not a personal recommendation.
| Formulation | Typical practical pattern | Potential advantages | Important limitations |
|---|---|---|---|
| Testosterone gel | Applied to clean, dry skin every day according to the product instructions | Needle-free; dose can be adjusted; treatment can be stopped quickly if needed | Daily routine; variable absorption; skin irritation; transfer risk to partners or children |
| Shorter-acting intramuscular testosterone ester injection | Administered at intervals determined by the licensed product and response | Less frequent than daily gel; established products | Injection discomfort; peaks and troughs may occur; haematocrit can rise; some products contain oils or excipients relevant to allergy |
| Long-acting testosterone undecanoate injection | Deep intramuscular injection administered by a healthcare professional at long intervals | Infrequent dosing; avoids daily application | Large-volume clinic injection; slow administration and observation requirements; slower to reverse; rare injection-related pulmonary oil microembolism risk |
UK products include testosterone gels such as Testogel and Tostran. They are applied daily to product-specific skin sites. Hands must be washed afterwards, the gel allowed to dry and the site managed to prevent transfer through skin contact. The patient information leaflet controls the exact application, washing, showering and contact instructions.
Gels can be useful when a reversible option is preferred or injection peaks are problematic. Absorption varies, so a standard number of pumps is not a universal dose. Blood-test timing and dose adjustment must follow the particular product.
Sustanon is a mixture of four testosterone esters in an oily intramuscular injection. Its UK product information states that the dose should be adjusted to the individual's response. It contains arachis oil and is contraindicated in people allergic to peanuts or soya.
Online clinics sometimes advertise more frequent or subcutaneous micro-dosing schedules. Those claims must be separated from the licensed product instructions and governed explicitly as off-label practice where relevant. A general guide should not teach a patient to redesign an injection schedule.
Testosterone enantate is a licensed intramuscular depot injection for confirmed male hypogonadism. Its product information describes administration intervals that are individualised using symptoms and trough testosterone levels.
The published intramuscular instructions should not be silently replaced by a different route. If a clinician recommends an off-label route or interval, the patient should be told what is off label, why it is being used, what evidence supports it and how it will be monitored.
Nebido and other testosterone undecanoate injections are long-acting intramuscular preparations administered under healthcare-professional guidance. UK product information requires very slow, deep gluteal injection and includes precautions intended to reduce pulmonary oil microembolism and anaphylactic reactions.
The long interval is convenient for some men, but the medicine is not easy to remove once administered. That makes diagnostic confidence and early safety assessment especially important.
These may appear on private-clinic websites or in overseas content, but licensing, availability, route and evidence differ in the UK. Ask for the exact product, manufacturer, route and regulatory status rather than treating every form of “TRT” as interchangeable.
The decision should consider:
“Best TRT” has no context-free answer. The best choice is the one that corrects a confirmed deficiency, can be used correctly, fits the risk profile and can be monitored reliably.
Benefits depend on how low testosterone was before treatment, the symptom being measured and whether another condition is responsible. Evidence is strongest for improvement in sexual desire and other sexual symptoms in appropriately selected hypogonadal men. TRT may also:
Changes do not occur on one schedule. Sexual symptoms may begin to improve within months, while body composition and bone effects take longer. Energy, concentration and erectile function are less predictable because they often have multiple causes.
A commercial percentage such as “most men improve by 12 weeks” only has meaning if the provider publishes who was measured, how symptoms were defined, how many men were followed, what treatment they received and how missing data were handled.
Testosterone stimulates red blood cell production. Haematocrit can rise too far, increasing concern about blood viscosity and thrombotic risk. Injectable formulations tend to cause erythrocytosis more often than topical formulations.
The EAU advises monitoring testosterone and haematocrit at three, six and 12 months after treatment begins and annually thereafter. A haematocrit above 54% requires treatment adjustment or withdrawal and may require venesection, followed by reassessment before treatment is reintroduced.
TRT suppresses LH, FSH and intratesticular testosterone. Sperm count can fall substantially or reach zero, and testicular volume may reduce. The effect is often reversible after stopping, but recovery can take months or longer and is not guaranteed on a personal timetable.
hCG or selective oestrogen receptor modulators are sometimes used in specialist fertility-preserving pathways, but they do not make fertility risk disappear. Their indication, UK licensing status, evidence and monitoring must be explained separately.
Acne, oily skin, hair changes, breast tenderness or gynaecomastia, ankle swelling and weight change can occur. Gel can irritate the skin and can transfer testosterone to another person if instructions are not followed.
Pain, bruising and inflammation can occur. Oily injections have rare but important risks if material enters the circulation. Long-acting testosterone undecanoate has specific administration and observation precautions. A patient should be trained only in a route the prescriber and product pathway allow.
Testosterone treatment can change PSA and prostate volume. Current EAU evidence does not show that physiological testosterone therapy causes prostate cancer, but men with active advanced disease are not candidates and long-term data have limits. Baseline risk assessment and appropriate follow-up remain necessary.
New difficulty urinating, blood in urine or semen, a marked PSA change or other concerning symptoms need clinical review rather than automatic dose adjustment.
The EAU concludes that there is no substantive evidence that testosterone replaced to normal levels causes major adverse cardiovascular events, while advising caution and close monitoring in men with established cardiovascular disease, venous thromboembolism or heart failure. Testosterone can also increase blood pressure or fluid retention in some settings.
This does not justify marketing TRT as cardiovascular prevention. Low testosterone can be a marker of poor health, and association is not proof that replacing it prevents every associated outcome.
Testosterone can be converted to dihydrotestosterone and oestradiol. In genetically susceptible men, androgen exposure may accelerate male-pattern hair loss. Oestradiol is necessary for male health, and a laboratory value should not be “crashed” simply because it is labelled oestrogen. Symptoms, assay quality and the overall hormone pattern matter.
Sleep apnoea deserves assessment because untreated disease can mimic low-testosterone symptoms and can increase the risk of raised haematocrit. Product information and guidelines differ in how they frame the evidence, so a man with suspected or poorly controlled sleep apnoea needs an individual plan rather than a blanket reassurance.
A safe baseline normally includes:
The prescription should include an agreed target, administration instructions, follow-up schedule and route for urgent concerns.
Monitoring must match the formulation and the patient. A useful structure is:
| Stage | What may be reviewed |
|---|---|
| Baseline | Symptoms, testosterone pattern, cause, fertility, haematocrit, prostate risk, blood pressure, metabolic and cardiovascular factors |
| Around 3 months | Symptoms, adverse effects, administration, correctly timed testosterone, haematocrit; PSA or other markers where indicated |
| Around 6 months | Benefit, safety, testosterone and haematocrit; formulation or dose problems; relevant prostate review |
| Around 12 months | Continued indication, symptom goals, testosterone, haematocrit, blood pressure, metabolic and prostate monitoring as appropriate |
| Annually when stable | Continued benefit-risk review and guideline-appropriate safety monitoring; more often for higher-risk men |
Timing of the testosterone sample changes by product. A trough result before an injection and a sample taken soon after an injection do not answer the same question. Gel levels also depend on application timing and contamination precautions. The clinical service should give written instructions for each formulation.
Monitoring should ask whether the original symptom improved. A normal result without benefit may mean the symptom had another cause. Continuing indefinitely because the number changed is not patient-centred care.
Yes, but the consequences depend on why treatment was started, the formulation, duration and the body's capacity to recover endogenous production. The original symptoms can return, and recovery of the hormonal axis and sperm production may take time.
There is no universal taper or “post-cycle therapy” suitable for self-management. Men considering a stop should agree a plan with the prescriber, particularly when fertility, severe symptoms or long-acting injections are involved. This deserves a dedicated guide because online stopping protocols frequently mix medical TRT with non-medical steroid use.
Both NHS and private clinicians should diagnose hypogonadism properly and prescribe within professional and legal standards. Access, appointment time, formulary, test logistics and follow-up models may differ.
A private fee does not create a different biological diagnosis. Be cautious if a clinic:
Ask direct questions:
Choose a provider that can explain why treatment is indicated, how risk will be managed and when treatment would be declined, rather than one that simply approves it fastest.
Correcting genuine deficiency can increase lean mass and support strength, especially with appropriate training and nutrition. TRT should not be prescribed to enhance muscle or performance in a man without hypogonadism.
Current evidence is more reassuring than older warnings when testosterone is replaced physiologically in properly selected men, but it does not remove the need for cardiovascular and prostate assessment. Men with active advanced prostate cancer, uncontrolled heart failure or significant risk factors require specific decisions.
The clinician may pause or reduce treatment, change formulation, investigate contributory causes and arrange venesection when clinically required. A value above 54% requires action under EAU guidance.
